The researchers found that the active substance Sildenafil, which is the basis of Viagra and Revatio, has shown positive results in the prevention and treatment of Alzheimer’s disease.
–
The British journal Nature Aging published the findings of a study of medical data from more than 7 million patients and found that Sildenafil was associated with a 69% reduction in the incidence of Alzheimer’s disease.
The authors of the study, conducted at the Institute of Genomic Medicine at the Cleveland Clinic in the United States, said that a series of clinical trials are needed to support the findings of this analysis and to test the effectiveness of the drug in patients with this disease.
Researchers have found that the accumulation of beta-amyloid and tau proteins does lead to the formation of abnormal agglomerations in the brain, being the main markers of the development of this neurodegenerative disease. Agerpres.
To date, none of the many clinical trials conducted in the last decade with molecules that promised to counteract these processes have yielded satisfactory results. Faced with this situation, the authors of the new analysis looked for among the more than 1,600 drugs already approved by the health authorities in the United States, some that could have a beneficial effect on both proteins at the same time.
“Sildenafil, which has significantly improved cognitive and memory patterns in preclinical patterns, has been shown to be the best candidate,” said Feixiong Cheng, lead author of the study published by Nature Aging.
The researchers found that patients taking Sidenafil had a 55% lower risk of developing Alzheimer’s disease within six years than those treated with Losartan – a candidate drug for Alzheimer’s – and a 65% lower risk of developing Alzheimer’s disease. lower than those treated with Metformin.
– .
